Open Access

VIEWPOINT

Mesenchymal stem cells derived secretome as an innovative cell-free therapeutic approach

by EJLAL ABU-EL-RUB^1,2,*, RAMADA R. KHASAWNEH¹, FATIMAH A. ALMAHASNEH¹, HANA M. ZEGALLAI^3,4

1 Department of Basic Medical Sciences, Faculty of Medicine, Yarmouk University, Irbid, 21163, Jordan
2 Physiology and Pathophysiology, Faculty of Medicine, University of Manitoba, Winnipeg, R3E0W2, Canada
3 Department of Pharmacology & Therapeutics, University of Manitoba, Winnipeg, R3E0W2, Canada
4 DREAM, Children’s Hospital Research Institute of Manitoba, Winnipeg, R3E0W2, Canada

* Corresponding Author: EJLAL ABU-EL-RUB. Email:

BIOCELL 2022, 46(4), 907-911. https://doi.org/10.32604/biocell.2022.018306

Received 15 July 2021; Accepted 29 August 2021; Issue published 15 December 2021

Abstract

The paracrine and immunomodulatory cytokines secreted by mesenchymal stem cells (MSCs), generally referred to as the MSCs derived secretome, has substantial potential for the treatment of many chronic and degenerative diseases. MSCs secretome contains both common and disease specific cytokines and modulators that can be beneficial against a wide range of chronic diseases. Herein, we discuss the MSCs secretome composition profile and its translational applicability and the challenges surrounding its use in clinical settings.

---

Keywords

---